Drug intelligence / Profile preview

recombinant anti human glp-1 receptor humanized monoclonal antibody

Development stage: Unknown
Lead developer: Self raised funds
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Injection

Overview

This drug is a recombinant humanized monoclonal antibody designed to target the human GLP-1 receptor. It is currently being investigated for the treatment of type 2 diabetes, specifically in patients whose condition is poorly controlled with metformin. The drug is administered via injection and aims to modulate blood glucose fluctuations and bone metabolism. Clinical studies are evaluating its efficacy and safety.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on recombinant anti human glp-1 receptor humanized monoclonal antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant anti human glp-1 receptor humanized monoclonal antibody.

Explore the full profile